دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 1,790,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 1,500,000 تومان- قیمت ویژه : 590,000تومان
Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer.
doi : 10.1200/JCO-25-01009
Volume 43(28) pgs. 3057-3140 October 1, 2025
Mediastinal Nodal Evaluation May Be Safely Omitted in Select Patients With Ground Glass-Dominant Lung Adenocarcinoma.
doi : 10.1200/JCO-25-01578
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial.
doi : 10.1200/JCO-25-00274
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study.
doi : 10.1200/JCO-24-02637
Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.
doi : 10.1200/JCO-25-00610
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
doi : 10.1200/JCO-25-00742
Phase II Study of 177Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers.
doi : 10.1200/JCO-25-00791
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.
doi : 10.1200/JCO-25-00210
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
doi : 10.1200/JCO-25-00663
Reply to: Pediatric and Adolescent Considerations for the Revised ASCO Guidelines.
doi : 10.1200/JCO-25-01317
UKALL 2011: Flawed Noninferiority and Overlooked Interactions Undermine Conclusions.
doi : 10.1200/JCO-25-00919
Understanding the Potential Importance of Pharmacokinetic Variability in the Setting of ALL.
doi : 10.1200/JCO-25-01008
Reply to: "UKALL 2011: Flawed Noninferiority and Overlooked Interactions Undermine Conclusions" and "Understanding the Potential Importance of Pharmacokinetic Variability in the Setting of ALL".
doi : 10.1200/JCO-25-01468
Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
doi : 10.1200/JCO-25-01993
